322 related articles for article (PubMed ID: 26644411)
1. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Adjei AA; Richards DA; El-Khoueiry A; Braiteh F; Becerra CH; Stephenson JJ; Hezel AF; Sherman M; Garbo L; Leffingwell DP; Iverson C; Miner JN; Shen Z; Yeh LT; Gunawan S; Wilson DM; Manhard KJ; Rajagopalan P; Krissel H; Clendeninn NJ
Clin Cancer Res; 2016 May; 22(10):2368-76. PubMed ID: 26644411
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
Lim HY; Heo J; Choi HJ; Lin CY; Yoon JH; Hsu C; Rau KM; Poon RT; Yeo W; Park JW; Tay MH; Hsieh WS; Kappeler C; Rajagopalan P; Krissel H; Jeffers M; Yen CJ; Tak WY
Clin Cancer Res; 2014 Dec; 20(23):5976-85. PubMed ID: 25294897
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Weekes CD; Von Hoff DD; Adjei AA; Leffingwell DP; Eckhardt SG; Gore L; Lewis KD; Weiss GJ; Ramanathan RK; Dy GK; Ma WW; Sheedy B; Iverson C; Miner JN; Shen Z; Yeh LT; Dubowy RL; Jeffers M; Rajagopalan P; Clendeninn NJ
Clin Cancer Res; 2013 Mar; 19(5):1232-43. PubMed ID: 23434733
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
Widemann BC; Kim A; Fox E; Baruchel S; Adamson PC; Ingle AM; Glade Bender J; Burke M; Weigel B; Stempak D; Balis FM; Blaney SM
Clin Cancer Res; 2012 Nov; 18(21):6011-22. PubMed ID: 22962440
[TBL] [Abstract][Full Text] [Related]
5. No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects.
Huang F; Ajavon A; Huang E; Lettieri J; Liu R; Peña C; Berse M
Thyroid; 2017 Sep; 27(9):1118-1127. PubMed ID: 28741453
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
Kim A; Widemann BC; Krailo M; Jayaprakash N; Fox E; Weigel B; Blaney SM
Pediatr Blood Cancer; 2015 Sep; 62(9):1562-6. PubMed ID: 26207356
[TBL] [Abstract][Full Text] [Related]
7. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with
Lim HY; Merle P; Weiss KH; Yau T; Ross P; Mazzaferro V; Blanc JF; Ma YT; Yen CJ; Kocsis J; Choo SP; Sukeepaisarnjaroen W; Gérolami R; Dufour JF; Gane EJ; Ryoo BY; Peck-Radosavljevic M; Dao T; Yeo W; Lamlertthon W; Thongsawat S; Teufel M; Roth K; Reis D; Childs BH; Krissel H; Llovet JM
Clin Cancer Res; 2018 Oct; 24(19):4650-4661. PubMed ID: 29950351
[No Abstract] [Full Text] [Related]
8. Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Schmieder R; Puehler F; Neuhaus R; Kissel M; Adjei AA; Miner JN; Mumberg D; Ziegelbauer K; Scholz A
Neoplasia; 2013 Oct; 15(10):1161-71. PubMed ID: 24204195
[TBL] [Abstract][Full Text] [Related]
9. Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.
Reed DR; Mascarenhas L; Manning K; Hale GA; Goldberg J; Gill J; Sandler E; Isakoff MS; Smith T; Caracciolo J; Lush RM; Juan TH; Lee JK; Neuger AM; Sullivan DM
Cancer Med; 2016 Feb; 5(2):294-303. PubMed ID: 26714427
[TBL] [Abstract][Full Text] [Related]
10. Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
Cai Z; Wang C; Liu P; Shen P; Han Y; Liu N
Phytomedicine; 2016 Nov; 23(12):1295-1300. PubMed ID: 27765348
[TBL] [Abstract][Full Text] [Related]
11. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
Van Laethem JL; Riess H; Jassem J; Haas M; Martens UM; Weekes C; Peeters M; Ross P; Bridgewater J; Melichar B; Cascinu S; Saramak P; Michl P; Van Brummelen D; Zaniboni A; Schmiegel W; Dueland S; Giurescu M; Garosi VL; Roth K; Schulz A; Seidel H; Rajagopalan P; Teufel M; Childs BH
Target Oncol; 2017 Feb; 12(1):97-109. PubMed ID: 27975152
[TBL] [Abstract][Full Text] [Related]
13. Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.
Toffalorio F; Spitaleri G; Catania C; Dal Zotto L; Noberasco C; Delmonte A; Santarpia M; Vecchio F; Brunelli V; Rampinelli C; Barberis M; Fumagalli C; Zucchetti M; Zangarini M; Diena T; Danesi R; de Braud F; De Pas T
Oncologist; 2014 Apr; 19(4):344-5. PubMed ID: 24674875
[TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG
J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968
[TBL] [Abstract][Full Text] [Related]
15. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Fukudo M; Ito T; Mizuno T; Shinsako K; Hatano E; Uemoto S; Kamba T; Yamasaki T; Ogawa O; Seno H; Chiba T; Matsubara K
Clin Pharmacokinet; 2014 Feb; 53(2):185-96. PubMed ID: 24135988
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
Puzanov I; Sosman J; Santoro A; Saif MW; Goff L; Dy GK; Zucali P; Means-Powell JA; Ma WW; Simonelli M; Martell R; Chai F; Lamar M; Savage RE; Schwartz B; Adjei AA
Invest New Drugs; 2015 Feb; 33(1):159-68. PubMed ID: 25294187
[TBL] [Abstract][Full Text] [Related]
17. MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.
Facciorusso A; Licinio R; Carr BI; Di Leo A; Barone M
Expert Rev Gastroenterol Hepatol; 2015 Jul; 9(7):993-1003. PubMed ID: 25915713
[TBL] [Abstract][Full Text] [Related]
18. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.
Parvinian A; Casadaban LC; Hauck ZZ; van Breemen RB; Gaba RC
Diagn Interv Radiol; 2015; 21(3):235-40. PubMed ID: 25835078
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
Naito S; Sakai H; Hashine K; Tomita Y; Shinohara N; Fujisawa M; Eto M; Ozono S; Akaza H
Ann Oncol; 2015 Sep; 26(9):1871-1876. PubMed ID: 26117830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]